Goldman Sachs Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $26

Benzinga Newsdesk www.benzinga.com Neutral 49.6%

Neg 0% Neu 49.6% Pos 0%

Goldman Sachs analyst Salveen Richter initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $26.